Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
A significant proportion of healthcare professionals still tend to favor branded drugs
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Subscribe To Our Newsletter & Stay Updated
